Interventional Glaucoma

In light of an unprecedented year filled with technological advancements and pivots, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2021.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

In light of the ongoing COVID-19 pandemic, the Glaucoma Research Foundation will host a virtual Glaucoma 360 annual meeting in 2021.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

Goniotomy-viscodilation cataract surgery controls IOP without medications.

Innovation, change has dominated the glaucoma specialty over the years.

Programs use detection and treatment to ease burden of eye disease.

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

In this fourth installment on "2020 vision," pharmaceutical representatives share their outlook on what lies ahead for glaucoma innovations within the ophthalmic space.

Glaucoma Research Foundation (GRF) Ambassadors webinar provides platform for idea-sharing by ophthalmologists

Evidence-based medicine can lead to personalized care, better results for patients

One ophthalmic practice's staff has found that, despite the challenges faced healthcare professionals are facing amid the coronavirus pandemic, a few proverbial “silver lining” practice adaptations will endure long after the crisis is over.

Options can reduce the treatment burden for patients, leading to improved outcomes

Investigators note the need for less medication over 12-month period

How gonioscopy can offer ophthalmologists an option in treating patients with glaucoma

Researchers must weigh emotional, financial, and reputational considerations

Trabeculectomy may offer better results with more severe glaucoma

Technology is off to a good start, but improvements still needed

New research is looking past just regulating the IOP, using a single-cell RNA to identify 12 distinct cell types in trabecular meshwork.

Diagnostic and monitoring advances in glaucoma need fine-tuning

With an eye on innovation, money is driving research of new therapies and devices.

Canadian ophthalmologists receive updates on best practices amid coronavirus outbreak

Industry develops creative approaches to help increase patient medication adherence

Panel discusses IOP monitoring, drug delivery, data collection

Research finds automated segmentation software examines OCT scans

ICYMI: Nir Israeli, co-founder and CEO of Sanoculis discusses the company's new alternative surgical procedure for glaucoma designed to create a single-patient-use sterile tool and a multi-use external machine.

For many physicians, “moral injury” may be actual issue

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.